Can eribulin slow advanced cervical cancer? new trial results are in.
NCT ID NCT01676818
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a chemotherapy drug called eribulin in 32 people with advanced or recurrent cervical cancer that had spread or come back. The goal was to see how long the drug could keep the cancer from growing and to check for side effects. Participants had already received up to one prior chemotherapy treatment. The results help doctors understand if eribulin is a useful option for controlling this type of cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can adding radiation boost the power of immunotherapy in advanced cervical cancer?
- Can an immunotherapy-angiogenesis combo outshine standard chemo for advanced cervical cancer?
- Blood test may spot returning cervical cancer before symptoms appear
- New registry aims to learn from Real-World retreatment of gynecologic cancers
- Immunotherapy combo shows promise for advanced cervical cancer
- New combo therapy shows promise for Tough-to-Treat cervical cancer